Influvac S Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac S Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the matched B virus strains in individuals for whom seasonal vaccination is recommended.

GNH USA supplies Influvac S Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Influvac S Tetra is a quadrivalent influenza vaccine used to prevent seasonal influenza caused by specific B virus strains.

- Seasonal influenza (B strains): reduces the risk of illness, hospitalization, and complications associated with the matched B virus strains. - High‑risk populations: provides added protection for elderly, immunocompromised, and individuals with chronic health conditions. - Community health programs: supports public health initiatives aimed at lowering overall influenza transmission rates.

Like other injectable vaccines, Influvac S Tetra may be associated with local and systemic reactions.

Common Side Effects: - Pain at injection site: mild to moderate soreness lasting 1–3 days. - Redness or swelling: localized erythema that resolves within a few days. - Low‑grade fever: transient temperature rise, typically below 38.5 °C. - Headache: mild headache occurring within 24 hours post‑vaccination. - Muscle aches: transient myalgia lasting up to 48 hours.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported after influenza vaccination. - Seizures: uncommon occurrence, especially in individuals with a history of febrile seizures. - Thrombocytopenia: low platelet count observed in isolated cases. - Persistent high fever: fever >39 °C lasting more than 72 hours.

Prior to administration, healthcare professionals should consider the following precautions for Influvac S Tetra.

- Contraindication: Do not vaccinate individuals with a known severe allergy to any vaccine component. - Prior reaction: Defer vaccination in persons who experienced anaphylaxis after a previous influenza vaccine dose. - Acute illness: Postpone vaccination in patients with moderate or severe acute febrile illness until recovery. - Immunocompromised status: Assess risk‑benefit in patients receiving immunosuppressive therapy or with compromised immune systems. - Pregnancy and lactation: Use only if the potential benefit outweighs any potential risk; data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Influvac S Tetra may interact with certain medications or vaccines; awareness of these interactions helps ensure safety.

Major Interactions (Avoid): - Live attenuated vaccines: avoid administering within 4 weeks before or after Influvac S Tetra to prevent interference. - High‑dose corticosteroids: concurrent use may blunt the immune response to the vaccine. - Immunoglobulin therapy: intravenous immunoglobulin given within 2 weeks can reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antiviral drugs (e.g., oseltamivir): may be used concurrently but monitor for reduced antibody response. - Immunosuppressive agents (e.g., methotrexate): continue therapy but assess serologic response after vaccination. - Fever‑reducing medications (e.g., acetaminophen): may be taken to manage post‑vaccination symptoms without affecting efficacy.